Taipei, Taiwan – August 26, 2025 – Reber Genetics Co., Ltd. ("Reber") today announced its participation in the 11th Asian Pig Veterinary Society Congress (APVS), to be held from November 9 to 12, 2025, in Fukuoka, Japan. As a leading event for pig health and veterinary medicine in Asia, APVS provides a prime opportunity for Reber to showcase its latest achievements in pig vaccine research and development and to strengthen its business ties with global industry experts.
Driving Innovation in Animal Health
As a leader in Taiwan's animal vaccine R&D, Reber is dedicated to solving the major disease challenges faced by the swine industry. We understand the critical role of pig health management in global food security, which is why we continuously invest in developing effective and safe vaccine products. Our participation in APVS not only highlights our research efforts but also allows us to engage in in-depth discussions with veterinarians, academics, and industry partners from around the world. Together, we can explore how technological innovation can improve pig disease prevention and control.
Exhibit Highlights: Core Products and R&D Pipeline
Raibio Gene will be at Booth #23, strategically located right next to the booth of our Japanese business partner, Meiji Animal Health Co., Ltd. (Booth #1). This proximity is a testament to our close collaboration and a great opportunity to deepen our business relationship with Meiji Animal Health. We will use this platform to explore new strategies for expanding our high-quality products into the Japanese and broader Asia-Pacific markets, offering comprehensive disease prevention solutions to local pig farmers.
At our booth, we will introduce our core vaccine products, such as those for Porcine Reproductive and Respiratory Syndrome (PRRS). In addition, we will also reveal several innovative vaccine candidates currently in clinical trials, which are expected to provide even more comprehensive disease control options for the future.
Chia-Jung Frank Chang, Chief Technology Officer of Reber, stated: "We are very much looking forward to APVS 2025. This is an excellent platform to showcase Taiwan's strength in animal vaccine development to the world. We are confident that by exchanging insights with global experts, Raibio Gene will gain valuable experience to continuously improve our products and technology, contributing to the sustainable development of the swine industry in Asia and beyond."
About Reber Genetics Co., Ltd.
Reber Genetics Co., Ltd. is a biotech company specializing in the R&D, manufacturing, and sale of animal vaccines. With a strong R&D team and advanced production facilities, the company is committed to providing high-quality and effective disease prevention solutions for the livestock industry. Guided by its core values of "Innovation, Quality, and Service," Raibio Gene strives to improve animal health and promote industry sustainability.